Top Markets
Coin of the day
PaxMedica, Inc. Common Stock PaxMedica, Inc. Common Stock

PaxMedica, Inc. Common Stock

PXMD
Rankning i aktier #40912
PaxMedica, Inc. is a biopharmaceutical company currently in the clinical... PaxMedica, Inc. is a biopharmaceutical company currently in the clinical development phase, dedicated to advancing anti-purinergic drug therapies (APTs). These innovative treatments are specifically designed to address complex neurological disorders presenting with stubborn and persistent symptoms. The company's primary investigative drug is PAX-101, an intravenous (IV) form of suramin, which is being explored for a variety of conditions. These include autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, post-COVID-19 syndrome (commonly known as "long COVID"), and human African trypanosomiasis. Furthermore, PaxMedica is also developing PAX-102, an intranasal version of suramin, intended for various neurological applications. The company, which was incorporated in 2018 and has its headquarters in Tarrytown, New York, previously operated as Purinix Pharmaceuticals LLC before rebranding to PaxMedica, Inc. in April 2020. It functions as a subsidiary of Tardimed Sciences LLC.
Aktiekurs
$0.0005
Senast synkroniserad: 2026-08-12
Marknadsvärde
$63.13K
Förändring (1 dag)
0.00%
Förändring (1 år)
150.00%
Land
US
Handel PaxMedica, Inc. Common Stock (PXMD)

Kategori

EPS för PaxMedica, Inc. Common Stock (PXMD)
EPS per 2026 TTM: 0
Enligt PaxMedica, Inc. Common Stocks senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) 0. Vid slutet av 2026 hade bolaget ett EPS på 0, lika med EPS från 2026 som var 0.
EPS-historik för PaxMedica, Inc. Common Stock från 2026 till 2026
EPS vid slutet av varje år
År EPS Ändra
Inte tillräckligt med data för de angivna datumen.
EPS för liknande företag eller konkurrenter